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Abstract
Background—Rb1 is a ginsenoside steroid glycoside found exclusively in the plant Panax
ginseng. In an earlier report, we showed that Rb1 increased cell proliferation and reduced VEGF
(vascular endothelial growth factor) secretion by human retinal pigment epithelial (ARPE19) cells.
Objective—In the present study, we hypothesized that chemical modification of Rb1 changes the
level of VEGF secretion by ARPE19 cells.
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Method—Three derivatives of Rb1 were chemically synthesized by hydrogenation (Rb1-H2),
acetylation (Rb1-Acyl), and epoxidation (Rb1-Epoxy). Structural modifications were confirmed
by 1H Nuclear Magnetic Resonance (NMR) spectra and Mass Spectrometry (MS). To test the
biological activity, chemically modified compounds were added to cell culture media and
incubated for 72 hours at a concentration of 250 nM at 37°C. Conditioned media were collected
and cells were harvested/counted after treatment. Viable cell numbers were determined by the
trypan blue dye exclusion method and VEGF levels by Enzyme-Linked Immunosorbent Assays
(ELISA).
Results—Consistent with the prior report, results of the present study show Rb1 increased cell
proliferation and decreased VEGF secretion. Similar to Rb1’s effect on cell proliferation,
treatment with Rb1-H2, Rb1-Acyl and Rb1-Epoxy resulted in an increase in cell numbers. In
contrast to Rb1-induced decrease in VEGF secretion, treatment with Rb1-H2, Rb-Acyl and Rb1Epoxy resulted in increased VEGF levels.
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Conclusion—Chemical modifications of the ginsenoside Rb1 significantly affect the biological
activity of VEGF secretion by ARPE19 cells. Additional SAR (Structure Activity Relationship)
experiments will be conducted to study the detailed mechanisms by which how specific
modifications of Rb1 functional groups alter biological activities.
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INTRODUCTION
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Ginsenosides or panaxosides are a class of steroid glycosides, and triterpene saponins, found
exclusively in the plant genus Panax (ginseng). Although ginsenosides occur as a wide array
of structurally related analogues, only a few of the major components have received
attention due to trace occurrence and difficulty in isolation. Only major ginsenoside
components have been the target of research, as they are viewed as the active compounds
behind the claims of ginseng’s therapeutic efficacy. Individual ginsenosides appear to have
distinct effects [1]. Whereas one particular ginsenoside stimulates the central nervous
system, another sedates the central nervous system. Other ginsenosides produce different
effects as balancing metabolic processes, decreasing blood sugar, improving muscle tone,
stimulating the endocrine system and maintaining proper hormone levels. Research has
shown that ginseng is effective in maintaining and even restoring cellular functions and
therefore may reduce a number of symptoms of old-age [1]. Because ginsenosides appear to
affect multiple pathways, their mechanisms of action are complex and yet to be fully
elucidated.
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Some ginsenosides have been isolated to purity by column chromatography. Based on
structural differences, they are categorized into two main groups: the Rb1 group
(characterized by the presence of protopanaxadiol: Rb1, Rb2, Rc and Rd) and the Rg1 group
(characterized by the presence of protopanaxatriol: Rg1, Re, Rf, and Rg2) [2]. Recent
studies have shown that acetyl modifications to the protopanaxadiol saponin compounds
have notable activity against cancer cells [3]. In the present study, chemical modifications of
Rb1 by hydrogenation (Rb1-H2), acylation (Rb1-Acyl), and epoxidation (Rb1-Epoxy) were
performed and these Rb1 derivatives were tested (in ARPR-19 cells) to determine how their
biological activities were changed in comparison to the parent Rb1 compound.

Macular degeneration is a progressive eye disease affecting as many as 15 million
Americans and around 196 million globally. This disease attacks the macula of the eye,
where our sharpest central vision occurs. Although it rarely results in complete blindness, it
depletes the individual of all but the outermost, peripheral vision, leaving only dim images at
the center of vision. AMD (Age-related Macular Degeneration) is characterized by
angiogenesis, the abnormal growth of new blood vessels [4], which resulted in the leakage
of fluid and blood into the retina, inducing scar formation and destroying central vision.
AMD is a slow progressive disease associated with genetic as well as environmental risk
factors including cigarette smoking, diet and prolong intense light exposure [5, 6].
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Diabetic retinopathy is the result of retinal microvascular changes. Hyperglycemia-induced
intramural pericyte apoptosis and thickening of the basement membrane [7]. These damages
render retinal blood vessels more permeable. Pericyte death is associated with
“hyperglycemia persistently activates protein kinase C-3 and p38 Mitogen-Activated Protein
Kinase (MAPK), increasing the expression of PKC-3 signaling” [8, 9]. This signaling
cascade leads to Platelet-Derived Growth Factor (PDGF) receptor-dephosphorylation and a
reduction in downstream signaling from this receptor, resulting in pericyte apoptosis. An
over accumulation of glucose and/or fructose damages blood capillaries in the retina with
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fluid and lipids leakage to the macula, the region of the retina with high visual acuity. The
fluid accumulation results in the swelling (or edema) of the macula, which blurs vision [10].

The retinal pigment epithelium (RPE) plays a critical role in the development and
maintenance of adjacent photoreceptors in the vertebrate retina. The RPE and Bruch’s
Membrane (BM) endure significant damage over one’s lifetime and such age-related
changes are attributable to the development of AMD in certain individuals [11–13]. The
RPE is also responsible for phagocytosis and degradation of shed-photoreceptors’ outer
segments [14]. The disruption of this process may lead to retinal degradation, and the
initiation or progression of AMD in humans [15]. The RPE secretes angiogenic (VEGF) and
antiangiogenic (PEDF) cytokines, and therefore plays a key role in chorodial
neovascularization, which can lead to AMD and possibly other eye diseases. [16–18].
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Vascular endothelial growth factor (VEGF) is a cell signaling protein that stimulates
vasculogenesis and angiogenesis. It is part of the negative feedback loop that restores the
oxygen supply to tissues when blood is circulating. Serum concentration of VEGF is high in
bronchial asthma and diabetes mellitus [12]. VEGF’s normal function is to create new blood
vessels during embryonic development, new blood vessels after injury, muscle following
exercise, and new vessels (collateral circulation) to bypass blocked vessels. Solid cancers
cannot grow beyond a limited size without an adequate blood supply. However, cancers
express VEGF to increase blood supply by neovascularlization. Overexpression of VEGF
and other proteins cause vascular diseases such as diabetic retinopathy [12]. Drugs, such as
bevacizumab, inhibit VEGF to control or halt disease development [4].
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VEGF is member of the PDGF family of cysteine-knot growth factors. They are important
signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic
circulatory system) and angiogenesis (the growth of blood vessels from pre-existing
vasculature) [19]. In a previous study, we reported that Rb1 increases ARPE cell
proliferation and inhibits VEGF release. In the present study, we observed that ARPE-19
cells treated by chemically modified Rb1 also increased cell proliferation but they increase
VEGF secretion. The molecular mechanism of such drug action is not known.

MATERIALS AND METHODS
Rb1
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Rb1 was purchased from Fleton Natural Products (Chengdu, China) and was certified by
Fleton to be chemically pure (99.8% pure by HPLC analysis) with the ability to be used as
raw materials in food, drink, nutrition supplement and cosmetics field. The 1H NMR
spectrum of commercial Rb1 was identical to that appearing in the literature [6]. Chemical
modifications of Rb1 were carried out in the laboratory by standard organic reactions (Fig.
1) and are described in the following paragraphs. Each of the compounds prepared in these
studies was synthesized as previously reported, with modifications indicated below. The Pd
catalyst for the hydrogenation was prepared as described by Felpin [20] and used without
further purification. The m-CPBA oxidant was purified via liquid-liquid extraction using
Et2O and NaHCO3 (aq) prior to use. Acetic anhydride and pyridine were purchased from
Acros (Pittsburgh, PA) and used without purification. All reaction conditions were
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performed in the absence of light. All other solvents and reagents were used without
purification as obtained from the supplier.
Rb1-H2
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To a stirred solution of Rb1 (17.9 mg, 16.1 μmol) in MeOH (1.0 mL) was added 6 wt% of
Pd(OAc)2:10% Pd/C catalyst mixture (5:95) [20] in a reaction flask. Residue on glassware
was rinsed with MeOH (0.5 mL) and transferred to the reaction flask. The flask was filled
with N2 and placed on a Parr Shaker Hydrogenation Apparatus under H2 (30 psi) at room
temperature for 16 hours. The mixture was filtered through a filter paper on sintered glass
and the filtrate was evaporated under reduced pressure. The product, which was obtained in
quantitative yield, exhibited a 1H NMR spectrum identical to that of the known Rb1-H2 [21],
including the expected diagnostic loss of the triplet at δ 5.1 for the tri-substituted olefin
proton of Rb1 (Fig. 2A and B). The LCMS trace exhibited one major peak that was shown to
have expected m/z for Rb1-H2: MS (m/z) calcd for C54H93O23− [M-H] − 1109.6, found
1109.6.
Rb1-Acyl
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Acetic anhydride (0.60 μL, 6.76 μmol) was added to a reaction flask charged with Rb1 (5
mg) in pyridine (1.50 μL, 18.03 μmol) and the reaction was stirred at room temperature
overnight. The mixture was evaporated under vacuum (0.5 mm Hg) and residual pyridine,
acetic anhydride, and acetic acid were removed by co-evaporation with MeOH (3 × 1 mL)
under reduced pressure to yield a colorless oil in 96% yield. The 1H NMR spectrum of the
product (Rb1-Acyl) exhibited signals consistent with the formation of the desired product
[22] including the olefin triplet at δ 5.1 ppm, multiple singlets in the 2.0–2.2 ppm range
expected for the 7 acetyl methyl groups, and downfield shifted signals δ 3–4 ppm expected
for the C-Hs with the acetoxy groups (Fig. 2A and C). The LCMS trace exhibited one major
peak that was shown to be comprised of molecules with the expected m/z: MS (m/z) calcd
for C84H123O38+ [M+H]+ 1739.8, found 1739.8.
Rb1-Epoxide
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To a stirred solution of Rb1 (11.2 mg, 10.1 μmol) in MeOH (2 mL) was added m-CPBA (2.8
mg, 16.2 μmol) [23] and the reaction was stirred at room temperature overnight. The
reaction was concentrated in vacuo and the oil was chromatographed (reversed-phase
column chromatography using a C18 Sep-Pak and gradient elution from water to MeOH).
Evaporation and solvent removal by lyophilization gave Rb1-Epoxide in 24% yield. The
product exhibited a 1H NMR spectrum consistent with that of the data provided for known
Rb1-Epox [24], however we present the 1H NMR in d-MeOH for easier interpretation. The
spectrum included the loss of the diagnostic triplet at δ 5.1 for the tri-substituted olefin
substrate of the reaction (Fig. 2A and D). The LCMS trace exhibited one major peak that
was shown to have expected m/z of Rb1-Epoxy: MS (m/z) calcd for C54H91O24− [MH] − 1123.6, found 1123.6.
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Adult retinal pigment epithelial cells (ARPE19) were obtained from the American Type
Culture Center (ATCC) and grown to confluence in T75 flasks in Dulbecco’s Modified
Eagle Medium (DMEM)-F12 containing 5.5 mM glucose and 10% FBS at 37°C and 5%
CO2. Cell were seeded into 24-well plates at a density of 20,000 cells per well and incubated
for 24 hours at 37°C before treatments.
Introduction of Rb1 and Rb1 Modified Compounds to ARPE-19 Cells in Culture
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Compounds (Rb1, Rb1-H2, Rb1-Acyl, Rb1-Epoxy) were diluted into serum free medium
(DMEM: F12) to a final concentration of 250 nM. Each cell sample received a total of 250
nM of its respective treatment/compound and were incubated for 72 hrs at 37°C and 5%
CO2. DMSO (vehicle for Rb1) and appropriate vehicles for Rb1 modified compounds were
used as controls.
Cell Viability and Cytokine Determination
Cell viability was determined by the trypan-blue dye exclusion method (Cat No.
MT25900Cl; Corning via Fisher Scientific) and counting with a Neubauer hemacytometer.
VEGF cytokine concentration in conditioned media was determined by Enzyme-Linked
Immunosorbent Assay (ELISA) (Cat No. DVE00, R&D Systems, USA). Quantification of
samples was determined by comparison to VEGF standard calibration curve (supplied with
kit and performed per manufacturer’s instructions).

RESULTS
Chemical Modification of Rb1 by Hydrogenation, Acylation and Epoxidation

Author Manuscript

The hydrogenation and epoxidation transformations convert the double bond in native Rb1
ginsenoside (Fig. 1) to the corresponding saturated chain and epoxide, respectively. The
hydrogenation of Rb1 ginsenoside was confirmed upon observing the loss of the alkene
proton of the substrate at 5.1 ppm. The Rb1-H2 1H NMR spectrum exhibited all other
signals expected for the product (Fig. 2A and B). In contrast, the peracetylation converts all
of the hydroxyl groups to acetoxy groups, diminishing aqueous solubility. The presence of
the acetoxy group was confirmed by the appearance and appropriate integration of singlets
near 2.0 ppm (Fig. 2C). In the epoxidation reaction, the alkene proton of Rb1 ginsenoside
disappeared but other signals appeared as expected (Fig 2D). Rb1-Epoxy is anticipated to
exist as a mixture of diastereomers, though neither spectroscopy nor spectrometry provided
evidence for these stereoisomers.
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Morphology of ARPE19 Cells
Cells were grown to confluence at P9 in T75 flasks (Fig. 3A). Cell seeded into 1 ml well and
incubated for 24 hr exhibit morphology consistent with pre-confluent ARPE 19 cells (Fig.
3B). Cell treated with Rb1 and Rb1 derivatives exhibited similar morphology suggesting that
these compound did not induce major upregulation of protein expression and cell
differentiation.
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Increase in Viable Cells After 72h Treatment with Rb1 and Rb1-Modified Compounds
(Concentration = 250nM)
After treatment for 72 hrs, there was an increase of 33,000 cells between vehicle and Rb1
groups (Fig. 4). Likewise, there were also increases in viable cell numbers between vehicle
controls vs. treatments by Rb1 modified compounds: increase by 18,000 cells with Rb1-H2
treatment, 6,000 cells with Rb1-Acyl treatment and 22,000 cells with Rb1-Epoxy (n = 3 for
all data points; ±SEM, see Fig. 3). One-way analysis of variance shows a significant
treatment effects (F=50; r 30.001).
Decrease in VEGF Release by Rb1 Treatment and Increase VEGF Release by Rb1-H2, Rb1Acyl and Rb1-Epoxy After 72hrs with 250nM
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After 72 hrs of treatment, VEGF secretion from cells treated with Rb1 decreased from 0.05
pg/cell (without Rb1) to 0.02 pg/cell (with 250 nM Rb1; Fig. 5). Meanwhile, treatment by
Rb1-H2 resulted in an increase of VEGF to 0.21 pg/cell (Fig. 5). Treatment with Rb1-Acyl
resulted in the highest level of increase VEGF (to 0.33 pg/cell) while treatment with Rb1Epoxy resulted in a much lower level of VEGF increase (to 0.05 pg/ml). Vehicle added to
the conditioned media did not induce any changes in VEGF from control (0mM Rb1). (n = 3
for all data points; ±SEM). One-way analysis of variance shows a significant treatment
effects (F=30; r 30.001).

DISCUSSION
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Previous reports have shown that Rb1 possesses potent anti-angiogenic activity in both invivo and in-vitro studies [14, 3]. Results from the present study are consistent with those
from our previous report that Rb1 induces ARPE-19 cell proliferation and inhibits VEGF
secretion [14]. However, it is not known if chemical modifications of Rb1 could impact the
efficacy of this cellular activity. Such a study on the structure versus function relationship
(SAR) is important because Rb1 affects a significant change in VEGF (a known
proangiogenic cytokine) secretion by RPE cells which are located near choroidal capillaries
and other ocular vasculatures in the eye, and are a major producer of VEGF which
contributes to the development of AMD and diabetic retinopathy.
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Results from the present study strongly suggest that chemical modifications of Rb1 led to
significant changes in its ability to induce cell proliferation and VEGF secretion. Chemically
modified Rb1s produced upon hydrogenation, acylation and epoxidation all induce cell
proliferation. In comparison to unmodified Rb1, epoxidation resulted in a slight increase in
the efficacy of Rb1 to induce cell proliferation whereas hydrogenation resulted in a
somewhat lower level of increase in cell proliferation (Fig. 4). In contrast, the addition of
acyl group significantly reduced Rb1’s ability to induce an increase in cell proliferation.
Although it is tempting to speculate that a change in hydrophobicity by the addition of the
acetyl group and the epoxide may correlate to the decrease and increase in this cell
(proliferation) activity, additional experiments are needed to substantiate this suggestion.
Further experiments can be carried out to study if changes in Rb1 efficacy on cell
proliferation are due to a change in its compatibility with hydrophobic cell membrane and/or
intracellular signaling including gene activation [25, 26]
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Results from the present study also show that chemical modification of Rb1 significantly
affects ARPE19 secretion of VEGF. Consistent with our prior report, the unmodified Rb1
inhibited VEGF secretion (see Fig. 5) [5]. In contrast, chemical modification of Rb1 by
hydrogenation, acylation and epoxidation resulted in an increase of VEGF release by
ARPE19. The addition of acetyl groups resulted in the highest level of change – about 7-fold
increase in VEGF release in comparison to control without Rb1. This is followed by
hydrogenation, which induced a 4-fold increase and by epoxidation, with a 2-fold increase in
VEGF release (compared to unmodified Rb1 which induced a 50% reduction in VEGF
release; Fig. 5). It is not clear at this time how such structural changes render such large
differences in this biological activity. Further experiments will be needed to investigate
underlying mechanisms.
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There are few pharmacokinetic and pharmacodynamic studies on the effects of Rb1 in
humans, and therefore the toxic levels of ginsenosides are currently unknown [27]. Betts et
al. [14] used concentrations of 0.25, 2.5, 25, and 250 nM Rb1 in an earlier experiment and
observed a significant decrease in VEGF with an increase in cell proliferation, and therefore
we chose to use 250 nM for all of our modified compounds in our experiment. Based on the
information presented in several studies [16, 17], retinal angiogenesis is not a fully
understood process in which retinal vascular endothelial cells proliferate and migrate
through the damaged membrane. Based on the results of this and similar studies, Rb1 and its
modified derivative Rb1H2 may be considered a viable homeopathic or pharmacological
treatment for ocular disease like AMD and diabetic retinopathy which involves the process
of choroidal neovascularization mediated by VEGF. This is the first study that compares the
effects of Rb1 and a hydrogenated form of Rb1, as well as acylation and epoxidation. These
modified compounds, compared to current therapy, could have a significant impact in the
diabetic retinopathy and AMD markets.

CONCLUSION
Chemical modifications of ginsenoside Rb1 significantly change its biological activities in
terms of cell viability and cytokine secretion by ARPE 19 cells. Additional experiments will
provide results to illustrate mechanistic insight on how these structure changes lead to
alternation of biological activities.
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LIST OF ABBREVIATIONS
AMD

Age-related Macular Degeneration

RPE

Retinal Pigment Epithelium

VEGF

Vascular Endothelial Growth Factor
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NMR

Nuclear Magnetic Resonance
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Ginsenoside
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Fig. (1).

Structure of Ginsenoside, Rb1 showing functional groups with chemical modification.
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Fig. (2).
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NMR Spectra of Rb1 and chemically modified Rb1. A) Rb1 without chemical modification.
B) Rb1-H2. C) Rb1-Acyl. D) Rb1-Epoxy. See “Result” section for a description on changes
in 1H NMR signals corresponding to hydrogenation, acylation and epoxidation of Rb1.
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Fig. (3).
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Photomicrographs of ARPE-19 cells in culture. A) confluent cells a Passage 9 after 5 days in
culture in a P75 flask, 100× magnification B) Cells at Passage 10 were seeded in a 1 ml well
at a seeding density of 20,000 cells per well and incubated for 24 hr in 37C, 5% CO, 200×
magnification.
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Fig. (4).

Increase in cell proliferation after with Rb1 and Rb1-modified compounds. Data in this
figure show the increase in viable cell number between vehicle control (0-Rb1) group and
group of cell with Rb1 (or Rb1 modified compounds) treatment at 250 nM for 72 hr. (n = 3
for all data points; ±SEM).
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Fig. (5).
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hVEGF secretion by ARPE 19 cells is inhibited by Rb1 and enhanced by Rb1H2, Epoxide,
or Rb1 Acylated Treatments. A) After 72 hrs, hVEGF secretion from cells treated with Rb1
at 250 nM decreased to 382 pg/mL (compared to 600 pg/mL in vehicle control of 0-Rb1)
whereas cells treated with Rb1-H2 at 250 nM increased to 659 pg/mL. Similarly, cell treated
with Rb1-Acyl increased to 1157 pg/mL and Rb1-Epoxy, increased to 657 pg/mL. B)
Compared to 0.05 pg/cell/mL in vehicle control of 0-Rb1, hVEGF decreased to 0.02 pg/cell
in respond to Rb1. In contrast, Rb1-H2 treatment increased hVEGF secretion to 0.21 pg/
cell/mL, Rb1-H2, to 0.33 pg/cell by Rb1-Acyl, and to 0.09 pg/cell by Rb1-Epoxy treatment
(n = 3 for all data points; ±SEM).
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